It was investigated whether endothelium-derived relaxing factor (EDRF) increases cyclic GMP (cGMP) content in platelets passing through the coronary bed. Boluses of washed platelets from healthy human donors were injected into the aortic perfusion line of isolated, saline-perfused rabbit hearts under constant flow conditions (28±2 ml/min). The coronary effluent was collected over 5 seconds, and the cGMP content of platelets was determined by radioimmunoassay. Platelet cGMP amounted to 0.34±0.11 pmol/mg protein after passage through the unstimulated coronary bed. During stimulation with acetylcholine (1 ju.M), it increased to 1.6±0.5 pmol/mg (p<0.01; n=14). Simultaneously, the platelet recovery (measured over 20 seconds after injection) was enhanced (by 45±11%; p<0.01) during endothelial stimulation with acetylcholine. Treatment with the EDRF inhibitor hemoglobin (6 /iM) completely abolished the increase in platelet cGMP (/><0.01; n = l l ) as well as the enhanced platelet recovery (n=8). Inhibition of EDRF by hemoglobin reduced also the basal platelet cGMP content to 0.17±0.11 pmol/mg (p<0.01). The data indicate that basally released EDRF is able to increase cGMP in platelets during a single passage through the coronary bed. The enhanced recovery of platelets after EDRF stimulation, which coincides with an increase of platelet cGMP, suggests that EDRF plays an important role as inhibitor of platelet activation in the coronary circulation. (Circulation Research 1989;65:1798-1803) E ndothelium-derived relaxing factor (EDRF), which is likely to be identical with nitric oxide, 1 exerts its vasodilator effects by a direct stimulation of soluble guanylate cyclase in smooth muscle cells.
EDRF Increases Cyclic GMP in Platelets
E ndothelium-derived relaxing factor (EDRF), which is likely to be identical with nitric oxide, 1 exerts its vasodilator effects by a direct stimulation of soluble guanylate cyclase in smooth muscle cells. 2 The fact that EDRF is also released toward the vascular lumen and that there is a high activity of soluble guanylate cyclase in platelets 3 has led to the concept that EDRF may be involved in the control of platelet activity. 4 Several in vitro studies have now established that EDRF is able to inhibit platelet aggregation and adhesion. 5 -8 An increase of platelet cyclic GMP (cGMP) has also been observed in the intact animal after prolonged (5 minutes) systemic exposure to the EDRFstimulator carbachol. 9 However, it is still unclear whether the basal release of EDRF in an intact vascular bed is sufficiently high to affect platelet cGMP levels. Moreover, it is unknown whether under conditions of high flow, EDRF can affect platelet cGMP level during a single passage through an organ. This would be a prerequisite for a physiological role of EDRF as antiplatelet agent in the intact circulation. We therefore studied whether EDRF-induced changes of cGMP levels can be observed in platelets after a single passage through the coronary beds of isolated perfused rabbit hearts. Furthermore, the effect of stimulation of EDRF release on platelet recovery in the coronary effluent was examined, which could be taken as an indicator of adhesion and aggregation in the coronary bed.
Materials and Methods

Langendorff Preparation
Mongrel rabbits (1.0-1.5 kg) of either sex were anesthetized with sodium pentobarbital (30-50 mg/ kg). After anticoagulation with heparin (5,000 units/ kg), one carotid artery was transsected. The heart was excised immediately after administration of a second (lethal) dose of sodium pentobarbital (50 mg/kg). Constant flow perfusion was performed by means of a roller pump (Heidolph RGL 85, Kelheim, FRG) through a cannula inserted into the aortic stump. The perfusion solution gassed with 95% O 2 -5% CO 2 to maintain a pH of 7.4, consisted of a modified Krebs-Henseleit buffer as described earlier. 10 Test solutions and platelet boluses were administered through a Y-shaped connector in the aortic perfusion line. Coronary perfusion pressure was measured with a pressure transducer (GouldStatham P 2310, Oxnard, California) through a side-branch of the aortic perfusion cannula. A fluidfilled latex balloon was inserted into the left ventricle through a pulmonary vein and connected to a second pressure transducer (Statham CP-01) to measure isovolumetric left ventricular pressure and heart rate, derived from the pressure signals by means of a cardiotachometer. The coronary effluent was collected from the coronary sinus or the right atrium respectively. Passage through the right ventricle was prevented by distraction of the atrioventricular valve and ligation of the pulmonary artery.
Preparation of Platelets
Blood from healthy human donors who had not received any medication was collected into 3.8% sodium citrate (20% of final volume). Platelet rich plasma (PRP) was obtained by centrifugation at 200,g for 20 minutes. After administration of acid citrate/dextrose (20 vol%) and prostacyclin (300 ng/ml), the PRP was centrifuged again and the pellet finally suspended in a modified Tyrode's solution containing indomethacin (1 ^M) to obtain a final platelet count of 2-3 xlO 6 platelets/jul. Experiments were finished within 180 minutes after the end of platelet preparation.
Platelet Cyclic GMP Content
The coronary effluent was collected over a period of 5 seconds after the injection of platelets into a tube containing trichloroacetic acid (TCA; final concentration 7%). After centrifugation, TCA was four times extracted from the supernatant with water-saturated ether, and the samples were kept frozen (-20° C) until analysis. Cyclic GMP was determined in the acetylated samples using a commercially available radioimmunoassay (New England Nuclear, Dreieich, FRG). Immediately before the injection of platelets, control samples of the coronary effluent were collected for determination of the cGMP content of the platelet-free effluent. The platelet cGMP content was calculated from the difference of both determinations and was normalized to the platelet protein.
Protein Content
The coronary effluent was collected in TCA and centrifuged as described above. The pellet was resuspended in 100 ix\ NaOH (1 M) and the protein content of the sample determined according to Lowry et al. 11 Platelet protein values were corrected for hemoglobin-derived protein during infusion of this EDRF inhibitor.
Determination of Prostacyclin Release
One milliliter each of platelet-free coronary effluent was collected before and during maximal dilation induced by acetylcholine (1 fjM). The samples were kept frozen until assayed for the content of 6-keto prostaglandin F la , the stable metabolite of prostacyclin, by means of a commercially available radioimmunoassay (New England Nuclear). The release was expressed in picograms 6-ketoprostaglandin F la per milliliter effluent and was normalized to a perfusion rate of 30 ml/min.
Experimental Protocol
After a 30-minute equilibration period, platelet boluses (300 pi) were injected in 10-minute intervals. Injections were performed under control (unstimulated) conditions and two minutes after the beginning of continuous administration of acetylcholine or adenosine (in random order) to the perfusate (final concentration 1 /xM each). The same protocol was repeated in the presence of hemoglobin. The coronary effluent was collected over 5 seconds after platelet injection and was assayed for cGMP content. In an additional series, the platelet passage through the coronary bed was studied under control conditions and during endothelial stimulation with acetylcholine. To this end, the protein content of the coronary effluent, collected over a period of 20 seconds after platelet injection, was assayed. The recovery of platelet protein in the effluent was expressed in percent of the amount of platelet protein administered during each bolus injection. The platelets were activated by 40 mU thrombin 20 seconds before bolus injection. Thrombin in this concentration did not induce any detectable effect on the coronary perfusion pressure. The experiments were performed in control hearts as well as in hearts exposed to indomethacin (30 pM for 30 minutes) or hemoglobin (6 fiM).
Statistics
Data are presented as means±SEM. Comparisons were performed by means of paired or unpaired t test. Differences were considered significant at a value of p<0.05. 12 
Drugs
Adenosine and acetylcholine-hydrochloride were obtained from Sigma, Deisenhofen, FRG, and freshly dissolved in Krebs-Henseleit buffer. Prostacyclin was a generous gift from Dr. Gertrud Schroder (Schering AG, Berlin). Indomethacin was dissolved in ethanol/0.1 NaHCO 3 , 1:3 vol/vol, and freshly diluted by Krebs-Henseleit buffer. Bovine hemoglobin (purchased from Sigma) was dissolved in 0.1 M phosphate buffer under nitrogen. After addition of sodium dithionite (10 mM), the stock solution was passed through a column packed with sepharose (CL-6B, Pharmacia, Freiburg, FRG). The hemoglobin fraction was collected in liquid nitrogen and kept frozen (-70° C) until the experiment was started. All drugs were infused through a Y-shaped connector in the aortic perfusion line at <3/100th of the coronary flow to produce the final concentrations described.
Results
Under constant flow conditions (mean flow: 28±2 ml/min corresponding to 509±30 ml/100 g/min) the infusion of acetylcholine (1 fiM) or adenosine (1 fiM) induced a significant decrease in perfusion pressure. It was similar in magnitude for both vasodilators (Table 1 ). In the presence of hemoglobin (6 (J.M), the vasodilator effect of adenosine remained unchanged, whereas the response to acetylcholine was severely attenuated or even was reversed to constriction (Table 1) .
Control values of the cGMP concentration in samples of the coronary effluent were determined immediately before injection of platelets and were 0.40±0.05 pg/ml under resting conditions, which was not significantly altered during infusion of acetylcholine (0.48±0.09 pg/ml) or adenosine (0.41 ±0.05 pg/ml). No protein could be detected in the coronary effluent in the absence of platelets. The cGMP content in effluent samples collected immediately after injection of platelets showed significant increases of the cGMP content compared with the respective controls by ll±10% (basal), 17±6% (adenosine), and 38±8% (acetylcholine). Figure 1 depicts the platelet-derived cGMP levels normalized by the respective platelet protein. During stimulation with acetylcholine, the platelet cGMP content was significantly elevated compared with the values obtained in unstimulated hearts or in the presence of adenosine, which were not significantly different from control. A similar increase of the platelet cGMP content was observed in the presence of 1 fiM sodium nitroprusside (to 1.65±0.3 pmol/mg; n=3). The cGMP increase during acetylcholine stimulation was completely abolished after infusion of the EDRF inhibitor hemoglobin. Moreover, the platelet cGMP content was significantly reduced compared with control ( Figure 1 ). After washout of hemoglobin, basal platelet cGMP was restored to control levels, and during acetylcholine stimulation, another significant, although smaller, increase of platelet cGMP was observed (Figure 1 ). In contrast, acetylcholine did not induce any change of cGMP content when incubated with samples of the same platelets in vitro (i.e., not being passed through the heart). Likewise, neither adenosine nor hemoglobin affected the platelet cGMP content during in vitro incubation (data not shown). By contrast, sodium nitroprusside induced a similar increase of platelet cGMP as observed during passage through the coronary bed (1.72±0.4 pmol/mg; n=3). In a separate series of experiments the recovery of platelets in the coronary effluent (determined as protein) was investigated. Under control conditions, 35±4% of the injected platelets could be detected during the collection period. In the presence of acetylcholine, the recovered fraction increased significantly (Figure 2 ). This increase was independent of concomitant changes in perfusion pressure since it was also observed during continuous infusion of papaverine, preventing further reduction of the perfusion pressure by acetylcholine (Table 2 ). In contrast, in the presence of hemoglobin, no significant increase of the platelet recovery was observed (n=8) (Figure 2 ).
. Platelet cyclic GMP (cGMP) content (picomoles per milligram platelet protein) after passage through the unstimulated heart (basal), during endotheliumderived relaxing factor stimulation with acetylcholine (ACh; I fiM) or during infusion of adenosine (ADO; 1 fjM). In the presence of the endothelium-derived relaxing factor inhibitor hemoglobin (Hb), basal cGMP and the ACh-induced increase are significantly suppressed. This inhibition is reversible after washout of hemoglobin. (n=ll-14
Acetylcholine induced a significant increase of the 6-keto prostaglandin F lct concentration in the coronary effluent, from 303±56 pg/ml to 966±225 pg/ml (p<0.01; n=5). After 30 minutes' infusion of indomethaein (30 fjiM) the release of prostacyclin was virtually completely suppressed (12±7 pg/ml) and no increase was observed during administration of acetylcholine (n=3). Nevertheless, there was still an increase of platelet recovery after administration of acetylcholine in hearts pretreated with indometh- acin (n=ll) (Figure 2 ). However, it was significantly (p<0.03) lower than under control conditions ( Figure 2 ).
Discussion
An increase in cytosolic cGMP has been shown to inhibit platelet activation. High levels of cGMP significantly reduce the agonist-induced increase of cytosolic calcium, 8 u ' 14 which plays a key role in the activation of platelets. 8 This is apparently the main mechanism by which cGMP inhibits platelet adhesion, The cGMP content of washed human platelets increased during a single passage through the coronary bed of isolated rabbit hearts. A roughly fivefold increase of cGMP was observed in the platelets when EDRF release from the coronary vasculature was stimulated by acetylcholine. Similar results were obtained with rabbit platelets (authors' unpublished data). The increase in platelet cGMP was most likely induced by EDRF, since treatment with the EDRF inhibitor hemoglobin completely abolished this increase as it inhibited the acetylcholineinduced vasodilation. Earlier experiments 17 have shown that the acetylcholine-induced dilation in the coronary microcirculation is mediated by EDRF. Moreover, in isolated hearts, an acetylcholineinduced release of EDRF (nitric oxide or its oxidation products) could be demonstrated directly. 18 It is important to note that the EDRF inhibitor hemoglobin not only blocked the cGMP increase during acetylcholine stimulation but also reduced the "unstimulated" cGMP level of platelets. This indicates that the cGMP level in platelets is already augmented when they pass the unstimulated heart and that the underlying mechanism can be inhibited by hemoglobin. Therefore, it can be concluded that the unstimulated coronary vasculature was able to release EDRF in considerable amounts. Our findings are consistent with observations in resistance vessels of the rabbit ear, 19 in isolated guinea pig hearts, 20 and isolated vessels,
21
-22 suggesting a basal release of EDRF. This continuous basal release might be sustained by physical stimuli-like flow, 23 -24 pulsatility, 23 or low oxygen partial pressure 26 and have considerable functional significance for the adjustment of blood flow to tissue metabolic demands. 1927 Our experiments demonstrate for the first time that this release is sufficient to increase platelet cGMP and therefore add a further piece of evidence that the basal EDRF release is functionally important. The relative increase of platelet cGMP by EDRF in the resting heart far exceeds 25%, which was found to be a threshold increase for a detectable inhibition of platelet activation in vitro. 28 Therefore, even the basal release of EDRF might exert a physiological function protecting against exaggerated platelet activity.
In contrast to experiments performed in test tubes, the EDRF effects on platelet cGMP were studied under conditions of high flow. The coronary flow (in milliliters per minute per 100 mg) was considerably higher than usually observed in animals in vivo and must have diluted the released EDRF substantially. Nevertheless, the increases in platelet cGMP were similaf to those measured after exposure to 1 ^M sodium nitroprusside, indicating that the amount of EDRF released was functionally equivalent to this high concentration of sodium nitroprusside.
One might infer that the inhibitory effect of oxyhemoglobin excludes such a role of EDRF under in vivo conditions since the concentrations of free hemoglobin in the plasma are in the range of 1 fiM. 29 However, our unpublished results as well as recent findings by Hogan et al 9 also show an EDRFmediated increase of platelet cGMP in vivo. The levels of free hemoglobin necessary to inhibit the EDRF-induced cGMP increase 9 were much higher than physiological plasma concentrations. This is in accordance with observations in microvessels indicating that luminally released EDRF might contrib-ute to downstream vasodilation at least over short distances. 30 - 31 Moreover, EDRF effects on platelets in vivo may be facilitated by the presence of erythrocytes in blood that, compared with saline perfusates, enhance the margination, and hence, the endothelial contact, of platelets. 32 The significant increase of platelet recovery during acetylcholineinduced EDRF stimulation is consistent with an inhibition of aggregation and/or adhesion in the coronary bed. Oxyhemoglobin abolished this enhanced recovery just as it inhibited the increase in platelet cGMP. In contrast, the inhibition of prostaglandin I 2 formation by indomethacin did not abolish the enhanced platelet recovery in response to acetylcholine. This indicates that, in our preparation, prostaglandin I 2 was less important than EDRF as a single antiaggregating and antiadhesive factor. This is in accordance with recent in vitro findings. 5 Nevertheless, prostaglandin I 2 may have functional significance in potentiating the inhibitory effects of EDRF, since indomethacin reduced the increase of the acetylcholine-induced platelet recovery to some extent. This is consistent with in vitro observations showing a potentiation of the effects of EDRF and certain nitrovasodilators on platelets by prostaglandin I 2 .i«. 33,j4 In summary, our study has shown, that in the isolated rabbit heart there is a basal release of EDRF in amounts sufficient to increase platelet cGMP. The platelet cGMP can be further increased by pharmacological stimulation of the endothelium. The association of increased platelet cGMP levels with an augmented recovery of platelets in the coronary effluent suggests that EDRF plays an important role as inhibitor of platelet activation in the coronary circulation.
